grepcent public filings, reorganized for comparison

HUMANA INC (HUM)

CIK: 0000049071. SIC: 6324 Hospital & Medical Service Plans. Latest 10-K as of: 2026-02-19.

SIC breadcrumb: Finance, Insurance, And Real Estate > Insurance Carriers > SIC 6324 Hospital & Medical Service Plans

SEC company page: https://www.sec.gov/edgar/browse/?CIK=49071. Latest filing source: 0000049071-26-000009.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-19 · accession 0000049071-26-000009 · source: SEC companyfacts

Revenue
129,664,000,000 USD verified
Net income
1,188,000,000 USD verified
Assets
48,909,000,000 USD verified
Free cash flow
375,000,000 USD computed
Net margin
0.92% computed
Operating margin
2.09% computed
Revenue YoY
+10.11% computed
ROE
6.73% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

Peer groups: Managed care and health insurers · SIC 6324 Hospital & Medical Service Plans

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer comparisons including HUM

Peer percentile fingerprint

HUM ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 6324; per-ratio N printed.HUM ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC industry 6324; per-ratio N printed.RatioHUMPeer medianPercentileNNet margin0.9%1.0%4410Operating margin2.1%1.3%6710Revenue growth10.1%12.2%010FCF margin0.3%2.2%259ROE6.7%5.9%5610ROA2.4%2.3%5610Liabilities / equity1.772.433310Current ratio2.001.5010010

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 6324 Hospital & Medical Service Plans, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue129,664,000,000USD20252026-02-19
Net income1,188,000,000USD20252026-02-19
Assets48,909,000,000USD20252026-02-19

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-19. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000049071.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric2016201720182019202020212022202320242025
Revenue54,379,000,00053,767,000,00056,912,000,00064,888,000,00077,155,000,00083,064,000,00092,870,000,000106,374,000,000117,761,000,000129,664,000,000
Net income614,000,0002,448,000,0001,683,000,0002,707,000,0003,367,000,0002,933,000,0002,806,000,0002,489,000,0001,207,000,0001,188,000,000
Operating income1,741,000,0004,262,000,0003,100,000,0003,192,000,0004,986,000,0003,148,000,0003,800,000,0004,013,000,0002,562,000,0002,704,000,000
Diluted EPS4.0716.8112.1620.1025.3122.6722.0820.009.989.84
Operating cash flow1,936,000,0004,051,000,0002,173,000,0005,284,000,0005,639,000,0002,262,000,0004,587,000,0003,981,000,0002,966,000,000921,000,000
Capital expenditures527,000,000524,000,000612,000,000736,000,000964,000,0001,342,000,0001,137,000,0001,004,000,000575,000,000546,000,000
Dividends paid177,000,000220,000,000265,000,000291,000,000323,000,000354,000,000392,000,000431,000,000431,000,000430,000,000
Share buybacks104,000,0003,365,000,0001,090,000,0001,070,000,0001,820,000,00079,000,0002,096,000,0001,573,000,000817,000,000151,000,000
Assets25,396,000,00027,178,000,00025,413,000,00029,074,000,00034,969,000,00044,358,000,00043,055,000,00047,065,000,00046,479,000,00048,909,000,000
Liabilities14,711,000,00017,336,000,00015,252,000,00017,037,000,00021,241,000,00028,255,000,00027,685,000,00030,747,000,00030,034,000,00031,172,000,000
Stockholders' equity10,685,000,0009,842,000,00010,161,000,00012,037,000,00013,728,000,00016,080,000,00015,311,000,00016,262,000,00016,375,000,00017,657,000,000
Cash and cash equivalents3,877,000,0004,042,000,0002,343,000,0004,054,000,0004,673,000,0003,394,000,0005,061,000,0004,694,000,0002,221,000,0004,200,000,000
Free cash flow1,409,000,0003,527,000,0001,561,000,0004,548,000,0004,675,000,000920,000,0003,450,000,0002,977,000,0002,391,000,000375,000,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric2016201720182019202020212022202320242025
Net margin1.13%4.55%2.96%4.17%4.36%3.53%3.02%2.34%1.02%0.92%
Operating margin3.20%7.93%5.45%4.92%6.46%3.79%4.09%3.77%2.18%2.09%
Return on equity5.75%24.87%16.56%22.49%24.53%18.24%18.33%15.31%7.37%6.73%
Return on assets2.42%9.01%6.62%9.31%9.63%6.61%6.52%5.29%2.60%2.43%
Liabilities / equity1.381.761.501.421.551.761.811.891.831.77
Current ratio2.071.851.681.821.771.621.521.591.762.00

Industry Peer Context

Each number-line places HUM against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

HUM Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.HUM Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -4.4%Median 1.0%Max 2.8%HUM 0.9%

Operating margin peer context

HUM Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.HUM Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -4.4%Median 1.3%Max 4.2%HUM 2.1%

ROE peer context

HUM ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.HUM ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -45.3%Median 5.9%Max 14.3%HUM 6.7%

ROA peer context

HUM ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.HUM ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 6324; peer count 10.10 SIC peersMin -15.8%Median 2.3%Max 4.7%HUM 2.4%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Free cash flow = operating cash flow - capital expenditures

HUM FY2025 free cash flow bridge from reported figures.HUM FY2025 free cash flow bridge from reported figures.HUM free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$500.0M$1.0B$921.0MOperating cash flow-$546.0MCapex$375.0MFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0000049071-26-000009; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0000049071-26-000009; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0000049071-26-000009; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

HUM revenue, last 5 periods. Source: SEC companyfacts FY2025.HUM revenue, last 5 periods. Source: SEC companyfacts FY2025.HUM RevenueLatest point: FY2025 = $129.7BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$75.0B$150.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: Revenues. Source concepts: us-gaap:Revenues.

HUM net income, last 5 periods. Source: SEC companyfacts FY2025.HUM net income, last 5 periods. Source: SEC companyfacts FY2025.HUM Net incomeLatest point: FY2025 = $1.2BSource: SEC companyfacts FY2025.Fiscal yearNet income$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

HUM operating income, last 5 periods. Source: SEC companyfacts FY2025.HUM operating income, last 5 periods. Source: SEC companyfacts FY2025.HUM Operating incomeLatest point: FY2025 = $2.7BSource: SEC companyfacts FY2025.Fiscal yearOperating income$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

HUM diluted eps, last 5 periods. Source: SEC companyfacts FY2025.HUM diluted eps, last 5 periods. Source: SEC companyfacts FY2025.HUM Diluted EPSLatest point: FY2025 = $9.84/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)$0.00/share$15.00/share$30.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

HUM operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.HUM operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.HUM Operating cash flowLatest point: FY2025 = $921.0MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

HUM capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.HUM capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.HUM Capital expendituresLatest point: FY2025 = $546.0MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

HUM dividends paid, last 5 periods. Source: SEC companyfacts FY2025.HUM dividends paid, last 5 periods. Source: SEC companyfacts FY2025.HUM Dividends paidLatest point: FY2025 = $430.0MSource: SEC companyfacts FY2025.Fiscal yearDividends paid$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: PaymentsOfDividends. Source concepts: us-gaap:PaymentsOfDividends.

HUM share buybacks, last 5 periods. Source: SEC companyfacts FY2025.HUM share buybacks, last 5 periods. Source: SEC companyfacts FY2025.HUM Share buybacksLatest point: FY2025 = $151.0MSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

HUM assets, last 5 periods. Source: SEC companyfacts FY2025.HUM assets, last 5 periods. Source: SEC companyfacts FY2025.HUM AssetsLatest point: FY2025 = $48.9BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$25.0B$50.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: Assets. Source concepts: us-gaap:Assets.

HUM liabilities, last 5 periods. Source: SEC companyfacts FY2025.HUM liabilities, last 5 periods. Source: SEC companyfacts FY2025.HUM LiabilitiesLatest point: FY2025 = $31.2BSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$20.0B$40.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

HUM stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.HUM stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.HUM Stockholders' equityLatest point: FY2025 = $17.7BSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$10.0B$20.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

HUM cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.HUM cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.HUM Cash and cash equivalentsLatest point: FY2025 = $4.2BSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$3.0B$6.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

HUM free cash flow, last 5 periods. Source: SEC companyfacts FY2025.HUM free cash flow, last 5 periods. Source: SEC companyfacts FY2025.HUM Free cash flowLatest point: FY2025 = $375.0MSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0000049071-26-000009; filed 2026-02-19. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

2 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-04-29. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000049071.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q22022-06-305.48reported discrete quarter
2022-Q32022-09-309.39reported discrete quarter
2023-Q12023-03-319.87reported discrete quarter
2023-Q22023-06-3026,747,000,000959,000,0007.66reported discrete quarter
2023-Q32023-09-3026,423,000,000832,000,0006.71reported discrete quarter
2023-Q42023-12-3126,462,000,000-541,000,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-3129,611,000,000741,000,0006.11reported discrete quarter
2024-Q22024-06-3029,540,000,000679,000,0005.62reported discrete quarter
2024-Q32024-09-3029,397,000,000480,000,0003.98reported discrete quarter
2024-Q42024-12-3129,213,000,000-693,000,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-3132,112,000,0001,244,000,00010.30reported discrete quarter
2025-Q22025-06-3032,388,000,000545,000,0004.51reported discrete quarter
2025-Q32025-09-3032,649,000,000195,000,0001.62reported discrete quarter
2025-Q42025-12-3132,515,000,000-796,000,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-3139,648,000,0001,186,000,0009.83reported discrete quarter

Quarterly Charts

HUM quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM Quarterly RevenueLatest point: 2026-Q1 = $39.6BSource: SEC companyfacts 2026-Q1.Fiscal quarterQuarterly Revenue$0.0B$20.0B$40.0B2023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0000049071-26-000023; filed 2026-04-29. Concept: Revenues. Source concepts: us-gaap:Revenues.

HUM quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM Quarterly Net incomeLatest point: 2026-Q1 = $1.2BSource: SEC companyfacts 2026-Q1.Fiscal quarterQuarterly Net income-$1.0B$0.0B$2.0B2023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0000049071-26-000023; filed 2026-04-29. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

HUM quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q1.HUM Quarterly Diluted EPSLatest point: 2026-Q1 = $9.83/shareSource: SEC companyfacts 2026-Q1.Fiscal quarterQuarterly Diluted EPS (USD/share)$0.00/share$7.50/share$15.00/share2022-Q22022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q1

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0000049071-26-000023; filed 2026-04-29. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read HUM's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read HUM's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0000049071-26-000050.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-07-29. Report date: 2026-06-30.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2025 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 19, 2026, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking

total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income, represents a statistic used to measure administrative spending efficiency.

MaxHealth Acquisition

On February 13, 2026, we acquired MaxHealth, a leading primary care platform focused on providing high-quality, integrated care to adults and senior patients throughout Florida, for cash consideration of approximately $908 million, net of cash acquired. This resulted in a preliminary purchase price allocation to goodwill of approximately $800 million, other intangible assets of $71 million, and net tangible assets acquired of $59 million. The other intangible assets, which primarily consist of member relationships and trade names, have an estimated weighted average useful life of 6.9 years. The purchase price allocation is preliminary, subject to completion of valuation analysis, including for example, refining assumptions used to calculate the fair value of intangible assets.

Value Creation Initiatives and Impairment Charges

In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions.

As a result of these initiatives, we recorded charges of $56 million and $154 million for the three and six months ended June 30, 2026, respectively, and $29 million and $53 million for the three and six months ended June 30, 2025, respectively, within operating costs in the consolidated statements of income. The charges primarily relate

35

Table of Contents

to severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. We expect to incur additional charges over the course of the program.

In addition, we recorded impairment charges related to minority-interest investments of $21 million within net investment income in our condensed consolidated statements of income for the three and six months ended June 30, 2026 and $32 million, relating to indefinite-lived intangible assets, within operating costs in our condensed consolidated statements of income for the three and six months ended June 30, 2025.

Business Segments

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. Our Chief Executive Officer, the Chief Operating Decision Maker, utilizes these segment groupings and results of each segment, measured by income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our stand-alone prescription drug plans, or PDP, and contracts with various states to provide Medicaid, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits. In addition, our Insurance segment includes our Military services business as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

Our Medicare benefit costs rise as members pay their contractual portion of claims responsibility, progress through their annual deductible and maximum out-of-pocket expenses, as well as incurring higher episodic cost of care resulting in a higher benefit ratio throughout the year.

Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our stand-alone PDP membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. The benefit design changes associated with the implementation of the Inflation Reduction Act of 2022, or IRA, reduced out-of-pocket costs for beneficiaries, resulting in greater cost sharing and a leveling of net prescription costs throughout the year. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the

second half of the year associated with the Medicare marketing season.

36

Table of Contents

2026 Highlights

•Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At June 30, 2026, approximately 4,118,700 members, or 64%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,542,300 members, or 68%, at June 30, 2025.

•Net income attributable to Humana was $694 million, or $5.73 per diluted common share, and $545 million, or $4.51 per diluted common share, for the three months ended June 30, 2026 and 2025, respectively. Net income attributable to Humana was $1.9 billion, or $15.55 per diluted common share, and $1.8 billion, or $14.81 per diluted common share, for the six months ended June 30, 2026 and 2025, respectively. These comparisons were impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, impairment charges and charges associated with value creation initiatives. The impact of these adjustments to our consolidated income before income taxes and equity in net losses and diluted earnings per common share was as follows for the 2026 and 2025 quarter and period:

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0000049071-26-000009. The complete FY 2025 MD&A is published at /company/HUM/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high. Filing date: 2026-02-19. Report date: 2025-12-31.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

For discussion of 2023 items and year-over-year comparisons between 2024 and 2023 that are not included in this 2025 Form 10-K, refer to "Item 7. – Management Discussion and Analysis of Financial Condition and Results of Operations" found in our Form 10-K for the year ended December 31, 2024, that was filed with the Securities and Exchange Commission on February 20, 2025.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for Medicare and Medicaid participants, families, individuals, military service personnel, and communities at large.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Employer Group Commercial Medical Products Business Exit

During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings were materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans.

Value Creation Initiatives and Impairment Charges

In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions.

As a result of these initiatives, we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively, primarily within operating costs in the consolidated statements of income. We expect to incur additional charges over the course of the program.

The value creation initiative charges primarily relate to $329 million, $25 million and $199 million in severance and other employee related charges in connection with workforce optimization in 2025, 2024 and 2023, respectively, as well as $40 million, $256 million and $237 million in asset impairments in 2025, 2024 and 2023, respectively. The remainder of the 2025 charges primarily relate to external consulting spend.

In addition, we recorded impairment charges of $253 million, $200 million and $91 million in 2025, 2024 and 2023, respectively. The impairment charges included impairment of indefinite-lived intangible assets for $128 million, $200 million and $55 million in 2025, 2024 and 2023, respectively, included within operating costs in our consolidated statements of income. The remaining impairment charges were included within investment income in our consolidated statements of income.

41

In addition to the value creation initiatives, we also recorded severance charges of $70 million in 2023 within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business.

Business Segments

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. Our Chief Executive Officer, the Chief Operating Decision Maker, utilizes these segment groupings and results of each segment, measured by income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates. For segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits. In addition, our Insurance segment includes our Military services business, primarily our T-5 East Region contract, as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

Our Medicare benefit costs rise as members pay their contractual portion of claims responsibility, progress through their annual deductible and maximum out-of-pocket expenses, as well as incurring higher episodic cost of care resulting in a higher benefit ratio throughout the year.

Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our stand-alone prescription drug plan, or PDP, membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. Effective January 1, 2025, the Medicare Part D coverage gap was eliminated as mandated by the Inflation Reduction Act of 2022, or IRA. The benefit design changes reduced out-of-pocket costs for beneficiaries, resulting in greater cost sharing and a leveling of net prescription costs throughout the year as compared to the historical seasonal decline prior to the IRA. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

42

The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season.

Highlights

•Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At December 31, 2025, approximately 3,586,100 members, or 68%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,994,300 members, or 71%, at December 31, 2024.

•Net income attributable to Humana was $1.2 billion, or $9.84 per diluted common share, and $1.2 billion, or $9.98 per diluted common share, in 2025 and 2024, respectively. This comparison was significantly impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, charges associated with value creation initiatives, impairment charges, loss on sale of business and settlement of certain litigation expenses. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2025 and 2024 periods:

20252024
(in millions)
Consolidated income before income taxes and equity in net losses:
Put/call valuation adjustments associated with our non-consolidating minority interest investments$513$296
Value creation initiatives449281
Impairment charges253200
Loss on sale of business67
Settlement of certain litigation expenses15
Total$1,297$777
20252024
Diluted earnings per common share:
Put/call valuation adjustments associated with our non-consolidating minority interest investments$4.25$2.45
Value creation initiatives3.722.33
Impairment charges2.091.65
Loss on sale of business0.55
Settlement of certain litigation expenses0.13
Cumulative net tax impact(3.36)(1.50)
Total$7.38$4.93

43

Regulatory Environment

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance i

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for HUM

Indicators mapped to this company's SIC classification (industry 6324 Hospital & Medical Service Plans) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Money & trade, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/HUM.md · JSON record: /company/HUM.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt